MARYKATHRINE WHEATLEY: Open Payments
NPI 1306382726 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$517 in 22 payments from 13 companies in 2025. Trend: 2023 $1,974 · 2024 $831 · 2025 $517
Food & beverage: $517
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| CSL Behring | 2 | $42 |
| GENZYME CORPORATION | 2 | $38 |
| Verona Pharma, Inc. | 1 | $31 |
| Amgen Inc. | 1 | $31 |
| GlaxoSmithKline, LLC. | 1 | $29 |
| Incyte Corporation | 1 | $29 |
| Genentech USA, Inc. | 1 | $29 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
Products named: FASENRA, DUPIXENT, EOHILIA, Ohtuvayre, TEZSPIRE, NUCALA, OPZELURA, CUVITRU.
Industry payments across CA — which companies pay providers there.
